This study is recruiting. It focuses on depression and currently lists participation information in the United States.
This study is looking at examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD) for people with Alzheimer Disease or depression. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
The official record suggests in-person participation through a research setting, with sites including NYU Langone Health in New York and Nathan S Kline Institute for Psychiatric Research in Orangeburg. Participation appears to involve using a digital tool or support program and giving feedback through check-ins or assessments. The main fit is usually matching the main diagnosis and meeting the main study requirements, while common reasons not to take part include major medical issues that could make participation unsuitable and active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means the approach is being followed in broader real-world use.
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring digital app or tool for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.
This study is sponsored by NYU Langone Health. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.
This study may involve digital app or tool, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.